Chemoradiotherapy improves survival after pancreatic adenocarcinoma resection
the ONA take:
Chemoradiotherapy was independently associated with improved overall survival after the resection of pancreatic adenocarcinoma, particularly among patients with R1 resection and pN1 disease, according to results from a large national cohort study published online ahead of print in the journal Cancer.
For the study, researchers sought to compare the effectiveness of chemotherapy with chemoradiotherapy in patients with pT1-3N0-1M0 pancreatic adenocarcinoma after pancreatectomy. Researchers identified 6,165 patients from the National Cancer Data Base who were treated with chemotherapy with or without radiotherapy.
Results showed that chemoradiotherapy was associated with improved overall survival vs chemotherapy alone. Subgroup analyses demonstrated that chemoradiotherapy was significantly associated with improved overall survival among those with pT3 or pN1 disease and both R0 resection and R1 resection.
The findings suggest that a prospective randomized head-to-head trial comparing adjuvant chemotherapy with chemoradiotherapy are warranted to assess their efficacy in patients with pancreatic adenocarcinoma who have undergone pancreatectomy.
Chemoradiotherapy was independently associated with improved overall survival after the resection of pancreatic adenocarcinoma.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|